---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T02:34:08.998623'
end_time: '2025-12-27T02:41:17.564552'
duration_seconds: 428.57
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: KCNRG
  gene_symbol: KCNRG
  uniprot_accession: Q8N5I3
  protein_description: 'RecName: Full=Potassium channel regulatory protein; Short=Potassium
    channel regulator; AltName: Full=Protein CLLD4;'
  gene_info: Name=KCNRG; Synonyms=CLLD4;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB.
    (IPR003131); BTB_2 (PF02214)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 25
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8N5I3
- **Protein Description:** RecName: Full=Potassium channel regulatory protein; Short=Potassium channel regulator; AltName: Full=Protein CLLD4;
- **Gene Information:** Name=KCNRG; Synonyms=CLLD4;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCNRG" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCNRG' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCNRG** (gene ID: KCNRG, UniProt: Q8N5I3) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8N5I3
- **Protein Description:** RecName: Full=Potassium channel regulatory protein; Short=Potassium channel regulator; AltName: Full=Protein CLLD4;
- **Gene Information:** Name=KCNRG; Synonyms=CLLD4;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCNRG" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCNRG' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCNRG** (gene ID: KCNRG, UniProt: Q8N5I3) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan overview: We verified KCNRG identity and organism, collected and analyzed foundational and recent sources (prioritizing 2023–2024), extracted mechanistic, localization, and disease-association evidence, and synthesized findings into a structured, well-cited report.

Research report: Human KCNRG (UniProt Q8N5I3)

1) Key concepts and definitions
- Identity and genomic context: KCNRG encodes a potassium channel regulatory protein within the chromosome 13q14.3 region frequently deleted in B‑cell malignancies. It lies adjacent to RFP2 and can be transcribed independently; the protein contains a single T1 (tetramerization) domain, which is distantly related to the BTB/POZ domain class that mediates protein–protein interactions. This domain is the N‑terminal cytoplasmic tetramerization module used by voltage‑gated K+ channel α‑subunits (Kv) to assemble, suggesting a mechanism for channel regulation (Molecular Biology, Mar 2004; URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa) (baranova2004structuralandfunctional pages 5-6).
- Isoforms and family: KCNRG produces two human protein isoforms sharing the common N‑terminus that includes the T1 domain: KCNRG‑L (272 aa) and KCNRG‑S (229 aa). KCNRG belongs to the non-channel T1/BTB (KCTD) family of proteins. In human tissues, the KCNRG‑L transcript is substantially more abundant than KCNRG‑S (reported ~300-fold higher mRNA) (Tumour Biology, Dec 2010 online Dec 18, 2009; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12, birerdinc2010proapoptoticandantiproliferative pages 5-7).
- Core concept of function: Based on homology to Kv tetramerization domains and experimental data with overexpression, KCNRG is proposed to bind Kv channel T1 domains and disrupt normal tetramer assembly/trafficking, thereby suppressing Kv currents (Tumour Biology, Dec 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 2-4, birerdinc2010proapoptoticandantiproliferative pages 1-2).

2) Recent developments and latest research (emphasis 2023–2024)
- APS‑1 cohorts and pulmonary autoimmunity: A 2024 prospective longitudinal French APECED/APS‑1 cohort (n=25) emphasized non‑endocrine manifestations including pulmonary involvement and referenced the clinical use of KCNRG autoantibodies (together with BPIFB1) as a lung disease marker in APS‑1, consistent with earlier work. Systematic immunologic profiling highlighted broad autoantibody spectra and frequent pulmonary involvement on screening (The Journal of Clinical Endocrinology & Metabolism, Apr 2024; URL: https://doi.org/10.1210/clinem/dgae211) (humbert2024lessonsfromprospective pages 10-12).
- Differential autoantibody landscapes in APS‑like phenotypes: A 2023 report of an APECED‑like case due to a de novo FAM111B variant (POIKTMP) specifically tested for APS‑1 pneumonitis autoantibodies and found BPIFB1 and KCNRG autoantibodies were not detected, underscoring that KCNRG autoantibodies are more characteristic of AIRE‑deficient APS‑1 pneumonitis and not universal to APS‑like diseases (Frontiers in Immunology, Feb 2023; URL: https://doi.org/10.3389/fimmu.2023.1133387) (ferre2023casereportdiscovery pages 3-5).
- Platelet ion channelome context (2021, integrative review with data tables): KCNRG appears in a curated list of “channel regulatory proteins” detected at transcriptomic level in human platelets, alongside Kv1.3 and accessory subunits (Platelets, Apr 2021; URL: https://doi.org/10.1080/09537104.2021.1904135) (wright2021whydoplatelets pages 1-3, wright2021whydoplatelets pages 3-4).

3) Molecular function, pathways, and localization
- Mechanism inferred from domain architecture and functional assays: KCNRG contains an N‑terminal cytoplasmic T1 domain homologous to Kv α‑subunit tetramerization domains. This suggests KCNRG can interact with Kv α‑subunits, perturb assembly of functional tetramers, and consequently reduce surface expression and ionic current. Supporting experiments show that overexpression of KCNRG isoforms in human cell lines reduces proliferation and induces apoptosis; the authors propose suppression of Kv currents via interference with T1‑mediated α‑subunit assembly (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (baranova2004structuralandfunctional pages 5-6, birerdinc2010proapoptoticandantiproliferative pages 2-4, birerdinc2010proapoptoticandantiproliferative pages 1-2, birerdinc2010proapoptoticandantiproliferative pages 5-7).
- Subcellular localization: KCNRG is described as a cytoplasmic protein with the T1/BTB-like domain; its mechanism implies interaction with Kv channels early in the biosynthetic pathway where tetramerization occurs (in cytoplasm/near ER entry), consistent with T1 domain biology (Molecular Biology, 2004; URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa) (baranova2004structuralandfunctional pages 5-6). Direct subcellular imaging for KCNRG is limited in available literature.
- Tissue expression and cellular sites of action: KCNRG transcripts are co-expressed across human tissues with KCNRG‑L dominant. Notably, in APS‑1 pulmonary disease, KCNRG antigen is enriched in epithelial cells of terminal bronchioles, consistent with its role as an autoantigen in pneumonitis (Pediatric Pulmonology, Jan 2012 online Sep 7, 2011; URL: https://doi.org/10.1002/ppul.21520) (popler2012autoimmunepolyendocrinesyndrome pages 1-3). In platelets, KCNRG is reported at transcript level as an accessory/regulatory protein candidate (Platelets, 2021; URL: https://doi.org/10.1080/09537104.2021.1904135) (wright2021whydoplatelets pages 3-4).

4) Disease associations and clinical relevance
- 13q14 deletion in CLL and MM; putative tumor suppressor: KCNRG resides in the minimal deleted region at 13q14.3 frequently lost in B‑cell chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Overexpression studies in RPMI‑8226 (MM), HL‑60 (myeloid), and LNCaP (prostate) cells demonstrated growth suppression and pro‑apoptotic effects, with caspase 3/6/7/9 and PARP cleavage; KCNRG‑L overexpression caused G2 arrest and reduced cell migration. Clinical expression profiling showed KCNRG‑L mRNA significantly lower in diffuse large B‑cell lymphoma than normal peripheral blood lymphocytes (P<0.002), and stage‑associated decreases across lymphoma cohorts, supporting a tumor suppressor role and possible haploinsufficiency mechanism in 13q14 loss contexts (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12, birerdinc2010proapoptoticandantiproliferative pages 12-13, birerdinc2010proapoptoticandantiproliferative pages 1-2). Earlier mapping work positioned KCNRG within 13q14.3 near RFP2, a region repeatedly implicated in CLL (Molecular Biology, 2004; URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa) (baranova2004structuralandfunctional pages 5-6).
- APS‑1 (AIRE deficiency) pulmonary disease: KCNRG is a recognized pulmonary autoantigen in APS‑1, with autoantibodies serving as a biomarker of active bronchiolitis/pneumonitis. In a pediatric APS‑1 case with severe pulmonary disease, KCNRG autoantibodies were positive and guided B‑cell–targeted therapy; rituximab improved symptoms, oxygen need, and obstruction on PFTs despite unchanged autoantibody titers, supporting clinical utility as a disease activity marker rather than a pharmacodynamic readout (Pediatric Pulmonology, 2012; URL: https://doi.org/10.1002/ppul.21520) (popler2012autoimmunepolyendocrinesyndrome pages 1-3, popler2012autoimmunepolyendocrinesyndrome pages 3-4). The 2024 French APS‑1 cohort reinforces the prominence of non‑endocrine manifestations including pulmonary disease and references KCNRG/BPIFB1 serology in surveillance (JCEM, 2024; URL: https://doi.org/10.1210/clinem/dgae211) (humbert2024lessonsfromprospective pages 10-12). A 2023 APS‑like POIKTMP case lacked KCNRG autoantibodies, underscoring syndrome specificity (Frontiers in Immunology, 2023; URL: https://doi.org/10.3389/fimmu.2023.1133387) (ferre2023casereportdiscovery pages 3-5).

5) Quantitative and experimental details
- Isoform abundance: KCNRG‑L mRNA ~300× higher than KCNRG‑S in human tissues examined (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12).
- Lymphoma expression and statistics: KCNRG‑L downregulated in diffuse large B‑cell lymphoma relative to normal PBLs (P<0.002), with stage‑linked reductions across cohorts; KCNRG‑S also decreased in early and IIE stages (reported P<0.008 and P<0.04, respectively) (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12).
- Functional phenotypes upon overexpression: In RPMI‑8226 and HL‑60 cells, KCNRG overexpression triggered apoptosis (caspase 3/6/7/9 and PARP cleavage), G2 arrest, reduced migration, and stress‑induced cell death propensity; methods included BrdU proliferation ELISA, CaspaseGLO 3/7 assays, Annexin V/7‑AAD FACS, and reverse‑phase protein microarrays indicating suppression of mTOR/VEGFR signaling (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12, birerdinc2010proapoptoticandantiproliferative pages 12-13, birerdinc2010proapoptoticandantiproliferative pages 2-4).
- APS‑1 pulmonary disease biomarkers and outcomes: In the 2012 case, KCNRG autoantibody positivity associated with bronchiolitis/bronchiectasis on CT, lymphoid aggregates on biopsy, and clinical improvement after rituximab, while an APS‑1 control without lung disease lacked KCNRG autoantibodies (Pediatric Pulmonology, 2012; URL: https://doi.org/10.1002/ppul.21520) (popler2012autoimmunepolyendocrinesyndrome pages 1-3, popler2012autoimmunepolyendocrinesyndrome pages 3-4). In the 2024 prospective APS‑1 cohort, 8/13 patients with lung function tests had impaired LFTs at baseline, highlighting frequent pulmonary involvement and the importance of systematic screening (JCEM, 2024; URL: https://doi.org/10.1210/clinem/dgae211) (humbert2024lessonsfromprospective pages 10-12).
- Platelet context: Kv1.3/KCa3.1 dominate platelet K+ conductances; KCNRG is listed among channel regulatory proteins detected at the transcript level in platelets, suggesting potential broader hematologic relevance though direct function in platelets remains to be established (Platelets, 2021; URL: https://doi.org/10.1080/09537104.2021.1904135) (wright2021whydoplatelets pages 3-4).

6) Current applications and real‑world implementations
- Clinical serology in APS‑1: KCNRG autoantibody testing is used in specialized centers to identify APS‑1 patients at risk for or with active pneumonitis/bronchiolitis, often alongside BPIFB1; positive serology may support initiating B‑cell–directed therapy (e.g., rituximab) when infection is excluded and histology shows lymphoid aggregates (Pediatric Pulmonology, 2012; URL: https://doi.org/10.1002/ppul.21520; JCEM, 2024; URL: https://doi.org/10.1210/clinem/dgae211) (popler2012autoimmunepolyendocrinesyndrome pages 1-3, popler2012autoimmunepolyendocrinesyndrome pages 3-4, humbert2024lessonsfromprospective pages 10-12).
- Oncology research: KCNRG is a putative tumor suppressor candidate in the 13q14 deletion landscape of CLL/MM. Expression profiling and functional overexpression studies inform biomarker exploration and mechanistic hypotheses for haploinsufficiency in B‑cell malignancies (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12, birerdinc2010proapoptoticandantiproliferative pages 12-13).

7) Expert opinions and analysis
- Domain‑based inference supports a model in which KCNRG acts as a soluble T1‑domain decoy/modulator for Kv α‑subunits, potentially limiting Kv channel assembly, surface trafficking, and current. The resulting effects—altered membrane potential, reduced Kv‑dependent signaling—could contribute to growth suppression and apoptosis observed upon overexpression. While direct electrophysiological suppression is proposed and patch‑clamp confirmation is referenced, detailed current magnitudes and channel‑specific partners remain to be comprehensively mapped in primary human cells (Molecular Biology, 2004; Tumour Biology, 2010; URLs above) (baranova2004structuralandfunctional pages 5-6, birerdinc2010proapoptoticandantiproliferative pages 2-4).
- In APS‑1, the emergence of KCNRG autoantibodies appears linked to bronchiolar epithelium autoimmunity. The 2024 prospective cohort underscores frequent non‑endocrine involvement and supports systematic surveillance including pulmonary evaluation and autoantibody testing, aligning with prior single‑center experiences using KCNRG/BPIFB1 serology to stratify lung disease risk and monitor activity (JCEM, 2024; Pediatric Pulmonology, 2012; URLs above) (humbert2024lessonsfromprospective pages 10-12, popler2012autoimmunepolyendocrinesyndrome pages 1-3).

8) Limitations and open questions
- Precise subcellular localization and partner mapping for KCNRG in native human cells require further study. Direct biochemical evidence for KCNRG–Kv T1 interactions and quantitative current suppression in primary cells are limited in the available literature; most functional data derive from overexpression systems (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 2-4, birerdinc2010proapoptoticandantiproliferative pages 10-12).
- The breadth of tissues expressing KCNRG protein (beyond mRNA) and its physiological roles in non‑disease settings remain incompletely defined. Platelet data list KCNRG at transcript level only, and functional roles in hematologic cells are not yet established (Platelets, 2021; URL: https://doi.org/10.1080/09537104.2021.1904135) (wright2021whydoplatelets pages 3-4).

Compliance with identification checks
- Gene symbol and protein match: Literature identifies KCNRG as “potassium channel‑regulating gene/protein” in human, aligning with the UniProt description and organism (Homo sapiens) (Molecular Biology, 2004; Tumour Biology, 2010; URLs above) (baranova2004structuralandfunctional pages 5-6, birerdinc2010proapoptoticandantiproliferative pages 1-2).
- Domains: KCNRG contains a single T1 domain distantly related to BTB/POZ, consistent with UniProt domain annotations (Molecular Biology, 2004; URL above) (baranova2004structuralandfunctional pages 5-6).
- Ambiguity: No conflicting gene with the KCNRG symbol in human was identified in the cited literature; studies consistently place KCNRG in 13q14.3 and relate to K+ channel regulation (baranova2004structuralandfunctional pages 5-6, birerdinc2010proapoptoticandantiproliferative pages 1-2).

References (URLs and dates)
- Baranova AV et al. Structural and functional characterization of human chromosome 13q14 and its potential tumor suppressor genes. Molecular Biology. Mar 2004. URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa (baranova2004structuralandfunctional pages 5-6).
- Birerdinc A et al. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology. Dec 2010 (online Dec 18, 2009). URL: https://doi.org/10.1007/s13277-009-0005-0 (birerdinc2010proapoptoticandantiproliferative pages 5-7, birerdinc2010proapoptoticandantiproliferative pages 1-2, birerdinc2010proapoptoticandantiproliferative pages 2-4, birerdinc2010proapoptoticandantiproliferative pages 12-13, birerdinc2010proapoptoticandantiproliferative pages 10-12).
- Popler J et al. Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatric Pulmonology. Jan 2012 (online Sep 7, 2011). URL: https://doi.org/10.1002/ppul.21520 (popler2012autoimmunepolyendocrinesyndrome pages 1-3, popler2012autoimmunepolyendocrinesyndrome pages 3-4).
- Humbert L et al. Lessons From Prospective Longitudinal Follow‑up of a French APECED Cohort. The Journal of Clinical Endocrinology & Metabolism. Apr 2024. URL: https://doi.org/10.1210/clinem/dgae211 (humbert2024lessonsfromprospective pages 10-12).
- Ferré EMN et al. Case report: Discovery of a de novo FAM111B pathogenic variant in a patient with an APECED‑like clinical phenotype. Frontiers in Immunology. Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133387 (ferre2023casereportdiscovery pages 3-5).
- Wright JR, Mahaut‑Smith MP. Why do platelets express K+ channels? Platelets. Published online Apr 19, 2021. URL: https://doi.org/10.1080/09537104.2021.1904135 (wright2021whydoplatelets pages 1-3, wright2021whydoplatelets pages 3-4).

References

1. (baranova2004structuralandfunctional pages 5-6): A. V. Baranova, D. V. Ivanov, T. V. Tyazhelova, and N. K. Yankovsky. Structural and functional characterization of human chromosome 13q14 and its potential tumor suppressor genes. Molecular Biology, 38:165-173, Mar 2004. URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa, doi:10.1023/b:mbil.0000023730.61501.aa. This article has 1 citations and is from a peer-reviewed journal.

2. (birerdinc2010proapoptoticandantiproliferative pages 10-12): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

3. (birerdinc2010proapoptoticandantiproliferative pages 5-7): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

4. (birerdinc2010proapoptoticandantiproliferative pages 2-4): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

5. (birerdinc2010proapoptoticandantiproliferative pages 1-2): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

6. (humbert2024lessonsfromprospective pages 10-12): Linda Humbert, Emmanuelle Proust-Lemoine, Sylvain Dubucquoi, Elisabeth Helen Kemp, Pascale Saugier-Veber, Nicole Fabien, Isabelle Raymond-Top, Catherine Cardot-Bauters, Jean-Claude Carel, Maryse Cartigny, Olivier Chabre, Philippe Chanson, Brigitte Delemer, Christine Do Cao, Laurence Guignat, Jean Emmanuel Kahn, Veronique Kerlan, Herve Lefebvre, Agnès Linglart, Roberto Mallone, Rachel Reynaud, Boualem Sendid, Pierre-François Souchon, Philippe Touraine, Jean-Louis Wémeau, and Marie-Christine Vantyghem. Lessons from prospective longitudinal follow-up of a french apeced cohort. The Journal of Clinical Endocrinology &amp; Metabolism, 110:e757-e773, Apr 2024. URL: https://doi.org/10.1210/clinem/dgae211, doi:10.1210/clinem/dgae211. This article has 5 citations.

7. (ferre2023casereportdiscovery pages 3-5): Elise M. N. Ferré, Yunting Yu, Vasileios Oikonomou, Anna Hilfanova, Chyi-Chia R. Lee, Lindsey B. Rosen, Peter D. Burbelo, Sara E. Vazquez, Mark S. Anderson, Amisha Barocha, Theo Heller, Ariane Soldatos, Steven M. Holland, Magdalena A. Walkiewicz, and Michail S. Lionakis. Case report: discovery of a de novo fam111b pathogenic variant in a patient with an apeced-like clinical phenotype. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133387, doi:10.3389/fimmu.2023.1133387. This article has 3 citations and is from a peer-reviewed journal.

8. (wright2021whydoplatelets pages 1-3): Joy R Wright and Martyn P. Mahaut-Smith. Why do platelets express k+ channels? Platelets, 32:872-879, Apr 2021. URL: https://doi.org/10.1080/09537104.2021.1904135, doi:10.1080/09537104.2021.1904135. This article has 16 citations and is from a peer-reviewed journal.

9. (wright2021whydoplatelets pages 3-4): Joy R Wright and Martyn P. Mahaut-Smith. Why do platelets express k+ channels? Platelets, 32:872-879, Apr 2021. URL: https://doi.org/10.1080/09537104.2021.1904135, doi:10.1080/09537104.2021.1904135. This article has 16 citations and is from a peer-reviewed journal.

10. (popler2012autoimmunepolyendocrinesyndrome pages 1-3): Jonathan Popler, Mohammad Alimohammadi, Olle Kämpe, Frida Dalin, Megan K. Dishop, Jennifer M. Barker, Margaret Moriarty‐Kelsey, Jennifer B. Soep, and Robin R. Deterding. Autoimmune polyendocrine syndrome type 1: utility of kcnrg autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatric Pulmonology, 47:84-87, Jan 2012. URL: https://doi.org/10.1002/ppul.21520, doi:10.1002/ppul.21520. This article has 55 citations and is from a peer-reviewed journal.

11. (birerdinc2010proapoptoticandantiproliferative pages 12-13): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

12. (popler2012autoimmunepolyendocrinesyndrome pages 3-4): Jonathan Popler, Mohammad Alimohammadi, Olle Kämpe, Frida Dalin, Megan K. Dishop, Jennifer M. Barker, Margaret Moriarty‐Kelsey, Jennifer B. Soep, and Robin R. Deterding. Autoimmune polyendocrine syndrome type 1: utility of kcnrg autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatric Pulmonology, 47:84-87, Jan 2012. URL: https://doi.org/10.1002/ppul.21520, doi:10.1002/ppul.21520. This article has 55 citations and is from a peer-reviewed journal.

## Citations

1. baranova2004structuralandfunctional pages 5-6
2. humbert2024lessonsfromprospective pages 10-12
3. ferre2023casereportdiscovery pages 3-5
4. popler2012autoimmunepolyendocrinesyndrome pages 1-3
5. wright2021whydoplatelets pages 3-4
6. birerdinc2010proapoptoticandantiproliferative pages 10-12
7. birerdinc2010proapoptoticandantiproliferative pages 5-7
8. birerdinc2010proapoptoticandantiproliferative pages 2-4
9. birerdinc2010proapoptoticandantiproliferative pages 1-2
10. wright2021whydoplatelets pages 1-3
11. birerdinc2010proapoptoticandantiproliferative pages 12-13
12. popler2012autoimmunepolyendocrinesyndrome pages 3-4
13. https://doi.org/10.1023/b:mbil.0000023730.61501.aa
14. https://doi.org/10.1007/s13277-009-0005-0
15. https://doi.org/10.1210/clinem/dgae211
16. https://doi.org/10.3389/fimmu.2023.1133387
17. https://doi.org/10.1080/09537104.2021.1904135
18. https://doi.org/10.1002/ppul.21520
19. https://doi.org/10.1002/ppul.21520;
20. https://doi.org/10.1023/b:mbil.0000023730.61501.aa,
21. https://doi.org/10.1007/s13277-009-0005-0,
22. https://doi.org/10.1210/clinem/dgae211,
23. https://doi.org/10.3389/fimmu.2023.1133387,
24. https://doi.org/10.1080/09537104.2021.1904135,
25. https://doi.org/10.1002/ppul.21520,